FDA Advisory Committees See ‘Red Flags’ in TIRF REMS

A FDA advisory committee raised concerns with the Risk Evaluation and Mitigation Strategy (REMS) for transmucosal immediate-release fentanyl (TIRF) products after reviewing data during a recent public meeting.